Managing the underestimated risk of statin-associated myopathy

International Journal of Cardiology

Volumn 159, Issue 3, 2012, Pages 169-176

  Rallidis, Loukianos S ^a   Fountoulaki, Katerina ^a   Anastasiou Nana, Maria ^a  

^a General University Hospital   (Greece)

Author keywords

Colesevelam; Ezetimibe; Rhabdomyolysis; Statin associated myopathy; Statins

Indexed keywords

ATORVASTATIN; COLESEVELAM; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

AGE; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; MYOPATHY; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHABDOMYOMA; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SIDE EFFECT; STATIN ASSOCIATED MYOPATHY; VULNERABLE POPULATION;

ANIMALS; DISEASE MANAGEMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84865499009     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.07.048     Document Type: Review

References (80)

1. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. M.H. Davidson, K.C. Maki, and T.A. Pearson Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am J Cardiol 96 2005 556 563
3. K. Kotseva, D. Wood, and G. De Backer Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
4. M.P. Hermans, M. Castro Cabezas, and T. Strandberg Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries Curr Med Res Opin 26 2010 445 454
5. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
6. L.S. Rallidis, C. Kotakos, and V. Sourides Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3 year follow-up Expert Opin Pharmacother 12 2011 1481 1489
7. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial Lancet 360 2002 7 22
8. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
9. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S) Lancet 344 1994 1383 1389
10. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
11. A. Kashani, C.O. Phillips, and J.M. Foody Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
12. G.A. Nichols, and C.E. Koro Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 Clin Ther 29 2007 1761 1770
13. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Bégaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
14. R.C. Pasternak, S.C. Smith Jr., and C.N. Bairey-Merz ACC/AHA/NHLBI clinical advisory on the use and safety of statins Circulation 106 2002 1024 1028
15. P.D. Thompson, P.M. Clarkson, R.S. Rosenson National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel An assessment of statin safety by muscle experts Am J Cardiol 97 2006 69C 76C
16. D.J. Graham, J.A. Staffa, and D. Shatin Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
17. C. Black, and H. Jick Etiology and frequency of rhabdomyolysis Pharmacotherapy 22 2002 1524 1526
18. K.A. Antons, C.D. Williams, S.K. Baker, and P.S. Phillips Clinical perspectives of statin-induced rhabdomyolysis Am J Med 119 2006 400 409
19. S. Cham, M.A. Evans, J.O. Denenberg, and B.A. Golomb Statin-associated muscle-related adverse effects: a case series of 354 patients Pharmacotherapy 30 2010 541 553
20. C.R. Harper, and T.A. Jacobson The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis Curr Opin Lipidol 18 2007 401 408
21. C. Vaklavas, Y.S. Chatzizisis, A. Ziakas, C. Zamboulis, and G.D. Giannoglou Molecular basis of statin-associated myopathy Atherosclerosis 202 2009 18 28
22. A.J. Dirks, and K.M. Jones Statin-induced apoptosis and skeletal myopathy Am J Physiol Cell Physiol 291 2006 C1208 C1212
23. C. Guijarro, L.M. Blanco-Colio, and M. Ortego 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ Res 83 1998 490 500
24. F.R. Westwood, A. Bigley, K. Randall, A.M. Marsden, and R.C. Scott Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity Toxicol Pathol 33 2005 246 257
25. O.P. Flint, B.A. Masters, R.E. Gregg, and S.K. Durham Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro Toxicol Appl Pharmacol 145 1997 91 98
26. S.K. Baker Molecular clues into the pathogenesis of statin-mediated muscle toxicity Muscle Nerve 31 2005 572 580
27. H. Päivä, K.M. Thelen, and R. Van Coster High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial Clin Pharmacol Ther 78 2005 60 68
28. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237
29. C.F. Schaars, and A.F. Stalenhoef Effects of ubiquinone (coenzyme Q10) on myopathy in statin users Curr Opin Lipidol 19 2008 553 557
30. F. Galli, and L. Iuliano Do statins cause myopathy by lowering vitamin E levels? Med Hypotheses 74 2010 707 709
31. C.V. Venero, and P.D. Thompson Managing statin myopathy Endocrinol Metab Clin North Am 38 2009 121 136
32. S.A. Siddiqi, and P.D. Thompson How do you treat patients with myalgia who take statins? Curr Atheroscler Rep 11 2009 9 14
33. B.A. Golomb Implications of statin adverse effects in the elderly Expert Opin Drug Saf 4 2005 389 397
34. A. Ghatak, O. Faheem, and P.D. Thompson The genetics of statin-induced myopathy Atherosclerosis 210 2010 337 343
35. SEARCH Collaborative Group E. Link, and S. Parish SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 2008 789 799
36. D. Voora, S.H. Shah, and I. Spasojevic The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
37. P. Zuccaro, G. Mombelli, L. Calabresi, D. Baldassarre, I. Palmi, and C.R. Sirtori Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin Pharmacol Res 55 2007 310 317
38. H. Sinzinger, and J. O'Grady Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems Br J Clin Pharmacol 57 2004 525 528
39. H. Sinzinger, P. Schmid, and J. O'Grady Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment Atherosclerosis 143 1999 459 460
40. A. Kulik, and M. Ruel Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety Expert Opin Drug Saf 8 2009 559 571
41. H. Desai, W.S. Aronow, and C. Ahn Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins Arch Gerontol Geriatr 51 2010 149 151
42. D. Poldermans Statins and noncardiac surgery: current evidence and practical considerations Cleve Clin J Med 76 Suppl. 4 2009 S79 S83
43. R.H. Eckel Approach to the patient who is intolerant of statin therapy J Clin Endocrinol Metab 95 2010 2015 2022
44. M.B. Bottorff Statin safety and drug interactions: clinical implications Am J Cardiol 97 8A 2006 27C 31C
45. J. Strandell, A. Bate, S. Hägg, and I.R. Edwards Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction Br J Clin Pharmacol 68 2009 427 434
46. P.H. Jones, and M.H. Davidson Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin Am J Cardiol 95 2005 120 122
47. J.M. Backes, P.A. Howard, J.F. Ruisinger, and P.M. Moriarty Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 43 2009 2012 2020
48. FDA Drug Safety Communication New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury http:/www.fda.gov/Drugs/DrugSafety Accessed June 8, 2011
49. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group J. Armitage, and L. Bowman Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
50. J.A. Staffa, J. Chang, and L. Green Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 346 2002 539 540
51. M.A. Silva, A.C. Swanson, P.J. Gandhi, and G.R. Tataronis Statin-related adverse events: a meta-analysis Clin Ther 28 2006 26 35
52. C.J. Glueck, B. Rawal, N.A. Khan, S. Yeramaneni, N. Goldenberg, and P. Wang Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 58 2009 233 238
53. P. Brancaccio, N. Maffulli, and F.M. Limongelli Creatine kinase monitoring in sport medicine Br Med Bull 81-82 2007 209 230
54. J.E. Lang, P. Wang, and C.J. Glueck Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism Clin Chim Acta 254 1996 65 92
55. P.S. Phillips, R.H. Haas, and S. Bannykh Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 2002 581 585
56. M.G. Mohaupt, R.H. Karas, and E.B. Babiychuk Association between statin-associated myopathy and skeletal muscle damage CMAJ 181 1-2 2009 E11 E18
57. T.A. Jacobson Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia Mayo Clin Proc 83 2008 687 700
58. A. Kashani, T. Sallam, S. Bheemreddy, D.L. Mann, Y. Wang, and J.M. Foody Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials Am J Cardiol 101 2008 1606 1613
59. H. Slim, and P.D. Thompson Ezetimibe-related myopathy: a systemic review J Clin Lipidol 2 2008 328 334
60. I.F. Gazi, S.S. Daskalopoulou, D.R. Nair, and D.P. Mikhailidis Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin Curr Med Res Opin 23 2007 2183 2192
61. L.A. Alvarez-Sala, V. Cachofeiro, and L. Masana Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized open-label, parallel-group study Clin Ther 30 2008 84 97
62. E.A. Stein, C.M. Ballantyne, and E. Windler Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am J Cardiol 101 2008 490 496
63. C.J. Glueck, D. Aregawi, and M. Agloria Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies Clin Ther 28 2006 933 942
64. J.M. Backes, C.V. Venero, and C.A. Gibson Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance Ann Pharmacother 42 2008 341 346
65. M. Gadarla, A.K. Kearns, and P.D. Thompson Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins Am J Cardiol 101 2008 1747 1748
66. J.M. Backes, P.M. Moriarty, J.F. Ruisinger, and C.A. Gibson Effects of once weekly rosuvastatin among patients with a prior statin intolerance Am J Cardiol 100 2007 554 555
67. J.F. Ruisinger, J.M. Backes, C.A. Gibson, and P.M. Moriarty Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol 103 2009 393 394
68. V.G. Athyros, K. Tziomalos, A.I. Kakafika, H. Koumaras, A. Karagiannis, and D.P. Mikhailidis Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients Am J Cardiol 101 2008 483 485
69. C.F. Huang, T.C. Li, C.C. Lin, C.S. Liu, H.C. Shih, and M.M. Lai Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients Eur J Cardiovasc Prev Rehabil 14 2007 438 440
70. D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 2009 830 839
71. S.C. Halbert, B. French, and R.Y. Gordon Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 105 2010 198 204
72. C.V. Venero, J.V. Venero, D.C. Wortham, and P.D. Thompson Lipid-lowering efficacy of red yeast rice in a population intolerant to statins Am J Cardiol 105 2010 664 666
73. F. Lapi, E. Gallo, and S. Bernasconi Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products Br J Clin Pharmacol 66 2008 572 574
74. C. Simard, and P. Poirier Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Can J Cardiol 22 2006 141 144
75. A. Corsini, E. Windler, and M. Farnier Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol Eur J Cardiovasc Prev Rehabil 16 2009 1 9
76. S.M. Rivers, M.P. Kane, R.S. Busch, G. Bakst, and R.A. Hamilton Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance Endocr Pract 13 2007 11 16
77. G.R. Thompson HEART-UK LDL Apheresis Working Group Recommendations for the use of LDL apheresis Atherosclerosis 198 2008 247 255
78. J.M. Young, C.M. Florkowski, and S.L. Molyneux Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia Am J Cardiol 100 2007 1400 1403
79. G. Caso, P. Kelly, M.A. McNurlan, and W.E. Lawson Effect of coenzyme q10 on myopathic symptoms in patients treated with statins Am J Cardiol 99 2007 1409 1412
80. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2